News ArchivesRead News
New regulator of circadian clock identified
Thursday October 21, 2010
EurekAlert - Daily sleeping and eating patterns are critical to human well-being and health. Now, a new study from Concordia University has demonstrated how the brain chemical dopamine regulates these cycles by altering the activity of the "clock-protein" PER2.
Published in the Journal of Neuroscience, these findings may have implications for individuals with Parkinson's Disease with disrupted 24-hour rhythms of activity and sleep.
"PER2 is a protein well-known for its role in the regulation of daily or circadian rhythms, this is why it is referred to as a clock protein," says senior author, Shimon Amir, a psychology professor at the Concordia Center for Studies in Behavioral Neurobiology. "Many molecules, such as stress hormones are known to have an impact on the activity of PER2.
Until now, the role of dopamine in regulating circadian rhythms has been unclear. Our findings show that not only is PER2 influenced by dopamine but also that dopamine is necessary for its rhythmic expression in specific brain regions."
Dopamine and Parkinson's
Parkinson's disease is caused by the degeneration of specific nerve cells, which results in a decrease in dopamine levels in the brain. Dopamine is critical for normal movements and balance and its decreased level results in instability and involuntary movements, the telltale symptoms of Parkinson's.
The findings from this Concordia study may explain the disruptions of daily behavioral and physiological rhythms that are also frequently reported in Parkinson's.
Rise in dopamine followed by rise in PER2
Amir and his colleagues studied the role of dopamine in rats. Their first steps were to show that PER2 is present in a specific brain area that normally receive dopamine, namely the dorsal striatum, and that it fluctuates daily in this area.
In this same region of the brain the research group demonstrated that a rise of dopamine preceded the rise in PER2 and that removing dopamine from the brain or blocking one of its receptors resulted in decreased PER2, which, in turn, could be reversed by the administration of a drug that mimics the action of dopamine on this receptor.
"Our findings are consistent with the idea that the rhythm of expression of PER2 depends on the daily activation by dopamine," says first author Suzanne Hood, a doctoral student at Concordia.
Recent NewsSep 12 - Australian Researchers Develop New Diagnostic Tool to Spot Early Signs of Parkinson’s
Sep 11 - GeneFo Webinar to Focus on Using Humor to Manage Parkinson’s Disease
Sep 6 - Parkinson’s and the ‘D’ word
Sep 6 - Compounds in Asthma Drugs Might Be Used as Parkinson’s Treatment
Sep 5 - AstraZeneca Joins Takeda, Berg to Advance Development of Parkinson’s Disease Therapies
Sep 1 - Stem Cell Transplant Trial in Parkinson’s Patients Planned After Test in Japan Succeeds in Monkeys
Sep 1 - Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s Patients
Aug 30 - FDA Refuses Acorda’s Inbrija New Drug Application Due to Manufacturing Questions
Aug 23 - Support Groups: Are They for You?
Aug 22 - Internet Visits with Parkinson’s Specialist Can Be as Effective as In-person Visits, Trial Finds
Aug 21 - Cavion’s New CMO to Lead Cav3 Platform Development for Neurological Diseases
Aug 15 - Singing Helps Early-stage Parkinson’s Patients Retain Speech, Respiratory Control, Studies Show
Aug 14 - 16 Tips to Increase Your Mobility Confidence While Living With Parkinson’s Disease
Aug 10 - Boxers are fighting back against Parkinson’s
Aug 9 - Parkinson’s Experiment to Be Aboard Next Flight to International Space Station
Aug 9 - Parkinson’s Disease and Sleeping with the Enemy
Aug 7 - The Importance of Oral Health in Parkinson’s Disease
Aug 7 - Researchers Gain Better Insight Into Alpha-Synuclein’s Role in Parkinson’s Disease
Jul 31 - New Digital Cognitive Assessment Tool Receives Positive FDA Review
Jul 20 - Parkinson’s DREAM Challenge Uses Mobile Sensor Data to Monitor Health Based on Movement